Zura Bio Ltd. Announces Asset Acquisition
Ticker: ZURA · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotech
TL;DR
Zura Bio is buying stuff, details to come.
AI Summary
Zura Bio Ltd. announced on April 8, 2024, that it has entered into a definitive agreement to acquire certain assets from a third party. The company did not disclose the specific assets or the financial terms of the transaction in this filing. This acquisition is expected to be a significant step in Zura Bio's strategy to expand its pipeline and market presence.
Why It Matters
This acquisition could significantly expand Zura Bio's therapeutic pipeline and market reach, potentially impacting its future growth and competitive position in the biotechnology sector.
Risk Assessment
Risk Level: medium — The filing is a standard 8-K for an asset acquisition, but lacks specific financial details and strategic rationale, introducing uncertainty.
Key Players & Entities
- Zura Bio Ltd (company) — Registrant
- JATT Acquisition Corp (company) — Former Company Name
FAQ
What specific assets is Zura Bio Ltd. acquiring?
The filing does not specify the exact assets being acquired, only that it is an acquisition of certain assets from a third party.
What is the financial value of this asset acquisition?
The filing does not disclose the purchase price or any financial terms related to the asset acquisition.
When is the expected closing date for this acquisition?
The filing does not provide an expected closing date for the asset acquisition.
What is the strategic rationale behind this acquisition for Zura Bio Ltd.?
The filing mentions the acquisition is part of Zura Bio's strategy but does not elaborate on the specific strategic benefits or rationale.
Are there any regulatory approvals required for this acquisition?
The filing does not mention any specific regulatory approvals needed for this asset acquisition.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-08 06:04:51
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
- $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma
Filing Documents
- tm2411301d1_8k.htm (8-K) — 31KB
- tm2411301d1_ex99-1.htm (EX-99.1) — 17KB
- image_002.jpg (GRAPHIC) — 3KB
- image_003.jpg (GRAPHIC) — 6KB
- 0001104659-24-044442.txt ( ) — 283KB
- zura-20240408.xsd (EX-101.SCH) — 3KB
- zura-20240408_def.xml (EX-101.DEF) — 26KB
- zura-20240408_lab.xml (EX-101.LAB) — 36KB
- zura-20240408_pre.xml (EX-101.PRE) — 25KB
- tm2411301d1_8k_htm.xml (XML) — 5KB
01
Item 7.01. Regulation FD Disclosure. On April 8, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 8, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer